Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Genmab ADR (NASDAQ: GMAB) closed at $31.5 in the last session, down -0.66% from day before closing price of $31.71. In other words, the price has decreased by -$0.66 from its previous closing price. On the day, 0.9 million shares were traded. GMAB stock price reached its highest trading level at $31.7414 during the session, while it also had its lowest trading level at $31.37.
Ratios:
We take a closer look at GMAB’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.69 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.54. For the most recent quarter (mrq), Quick Ratio is recorded 6.01 and its Current Ratio is at 6.03. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 17 ’25 when GENMAB A/S bought 150,795 shares for $97.00 per share. The transaction valued at 14,627,115 led to the insider holds 71,734,624 shares of the business.
GENMAB A/S bought 120,752 shares of GMAB for $11,712,944 on Dec 16 ’25. The 10% Owner now owns 71,583,829 shares after completing the transaction at $97.00 per share. On Jun 17 ’25, another insider, Klimovsky Judith V, who serves as the Director of the company, bought 1,300 shares for $51.69 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMAB now has a Market Capitalization of 19527931904 and an Enterprise Value of -1329631744. As of this moment, Genmab’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.38, and their Forward P/E ratio for the next fiscal year is 20.11. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.31. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.40 while its Price-to-Book (P/B) ratio in mrq is 3.37. Its current Enterprise Value per Revenue stands at -0.346 whereas that against EBITDA is -0.903.
Stock Price History:
The Beta on a monthly basis for GMAB is 0.89, which has changed by 0.5612998 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, GMAB has reached a high of $33.65, while it has fallen to a 52-week low of $17.24. The 50-Day Moving Average of the stock is 2.43%, while the 200-Day Moving Average is calculated to be 27.65%.
Shares Statistics:
According to the various share statistics, GMAB traded on average about 2.10M shares per day over the past 3-months and 1431860 shares per day over the past 10 days. A total of 615.99M shares are outstanding, with a floating share count of 615.99M. Insiders hold about 0.00% of the company’s shares, while institutions hold 10.31% stake in the company. Shares short for GMAB as of 1764288000 were 11896539 with a Short Ratio of 5.67, compared to 1761868800 on 10539384. Therefore, it implies a Short% of Shares Outstanding of 11896539 and a Short% of Float of 1.95.
Earnings Estimates
Investors are keenly observing as 4.0 analysts analyze and rate. The current performance of Genmab ADR (GMAB) in the stock market.The consensus estimate for the next quarter is $0.31, with high estimates of $0.31 and low estimates of $0.31.
Analysts are recommending an EPS of between $2.01 and $1.78 for the fiscal current year, implying an average EPS of $1.92. EPS for the following year is $1.51, with 5.0 analysts recommending between $2.58 and $1.01.
Revenue Estimates
According to 8 analysts,. The current quarter’s revenue is expected to be $6.57B. It ranges from a high estimate of $7.21B to a low estimate of $6.12B. As of. The current estimate, Genmab ADR’s year-ago sales were $6.44BFor the next quarter, 8 analysts are estimating revenue of $6.1B. There is a high estimate of $6.61B for the next quarter, whereas the lowest estimate is $5.24B.
A total of 16 analysts have provided revenue estimates for GMAB’s current fiscal year. The highest revenue estimate was $25.25B, while the lowest revenue estimate was $23.04B, resulting in an average revenue estimate of $23.81B. In the same quarter a year ago, actual revenue was $21.53BBased on 14 analysts’ estimates, the company’s revenue will be $27.48B in the next fiscal year. The high estimate is $29.32B and the low estimate is $24.82B.
